Essex Woodlands Healthcare Partners

VitalConnect is a company that specializes in wearable biosensor technology for wireless patient monitoring. It develops innovative solutions that enable continuous monitoring and recording of patients' vital signs through an adhesive patch applied to the body. The technology integrates expertise in biomedical engineering, data analytics, and chip design, allowing vital data to be displayed on mobile devices and computer systems. This capability empowers healthcare professionals to respond promptly to urgent situations and gain valuable insights into patient health, facilitating informed decision-making in both inpatient and outpatient settings, including hospital monitoring, post-discharge care, and cardiac monitoring.

Boiron is a prominent manufacturer of homeopathic medicines, known for its commitment to high manufacturing standards and adherence to Food and Drug Administration regulations, as well as the Homeopathic Pharmacopoeia. The company offers a diverse range of products, which are primarily divided into nonproprietary medicines and over-the-counter specialties. Nonproprietary medicines are generic and do not reference specific therapeutic indications, while the specialties include popular first-resort remedies available in various formats such as tablets, drops, syrups, and ointments. Boiron's product lineup features well-known items like Oscillococcinum, Stodal, and Arnigel. The company operates across multiple regions, with a significant portion of its revenue generated in France, alongside markets in Europe and North America. Additionally, Boiron has developed a mobile application for iOS users, further enhancing its engagement with consumers.

VitalConnect is a company that specializes in wearable biosensor technology for wireless patient monitoring. It develops innovative solutions that enable continuous monitoring and recording of patients' vital signs through an adhesive patch applied to the body. The technology integrates expertise in biomedical engineering, data analytics, and chip design, allowing vital data to be displayed on mobile devices and computer systems. This capability empowers healthcare professionals to respond promptly to urgent situations and gain valuable insights into patient health, facilitating informed decision-making in both inpatient and outpatient settings, including hospital monitoring, post-discharge care, and cardiac monitoring.

Enercon Technologies is an electronics manufacturing company that provides product development, testing, marketing, and design services.

TELA Bio, Inc. is a medical technology company based in Malvern, Pennsylvania, established in 2012. The company specializes in the design, development, and marketing of tissue reinforcement materials aimed at addressing unmet needs in soft tissue reconstruction. TELA Bio's primary offerings include the OviTex Reinforced Tissue Matrix products, which are utilized for hernia repair and abdominal wall reconstruction, as well as the OviTex PRS Reinforced Tissue Matrix products tailored for plastic and reconstructive surgery. Additionally, TELA Bio provides a version of OviTex specifically designed for laparoscopic and robotic-assisted procedures, which incorporates ovine rumen and polypropylene fiber for enhanced surgical outcomes. The company markets its products through a direct sales force, primarily within the United States, focusing on improving clinical outcomes and reducing healthcare costs associated with soft tissue repairs.

Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, specializing in the development and commercialization of minimally invasive and non-invasive devices and treatments. Its diverse product portfolio includes platforms such as Venus Versa, a multi-treatment solution for aesthetic procedures; Venus Legacy, designed for complex face and body needs; and Venus Viva, a customizable skin resurfacing device. The company also offers solutions for hair restoration, including NeoGraft and ARTAS robotic systems, which facilitate follicle harvesting and implantation. Other products address skin tightening, fat reduction, and vaginal health restoration. Venus Concept is recognized for its innovative approach and commitment to enhancing patient experiences within the medical aesthetics sector, generating a significant portion of its revenue from the United States.

Grundium Ltd, established in 2015 and headquartered in Tampere, Finland, specializes in imaging and multi-camera solutions. The company caters to diverse industries such as transportation, biotechnology, and professional imaging, offering end-to-end solutions that include hardware, software, and user services. Grundium's core expertise lies in providing high-quality, portable digital microscope scanners designed for live telepathology consultations, enabling real-time, high-resolution image transmission between surgeons and pathologists, regardless of location. This innovative technology enhances diagnostic pathology reach and quality while reducing time and costs. Additionally, Grundium provides multi-camera solutions for the transportation industry, capable of withstanding harsh environmental conditions, and offers microscopic imaging platforms for various applications.

VitalConnect is a company that specializes in wearable biosensor technology for wireless patient monitoring. It develops innovative solutions that enable continuous monitoring and recording of patients' vital signs through an adhesive patch applied to the body. The technology integrates expertise in biomedical engineering, data analytics, and chip design, allowing vital data to be displayed on mobile devices and computer systems. This capability empowers healthcare professionals to respond promptly to urgent situations and gain valuable insights into patient health, facilitating informed decision-making in both inpatient and outpatient settings, including hospital monitoring, post-discharge care, and cardiac monitoring.

Laboratoires Majorelle is an independent French pharmaceutical company dedicated to addressing significant public health concerns, particularly in the realm of sexual health. Founded with a mission to improve access to essential medicines, Majorelle specializes in providing solutions for contraception, sexually transmitted diseases (STDs), erectile disorders, and urinary incontinence. The company aims to offer comprehensive healthcare remedies that cater to both men and women in France, focusing on enhancing the quality of life through responsible pharmaceutical practices.

COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

Cardiva Medical, Inc. is a medical device company based in Santa Clara, California, specializing in innovative vascular access management products that facilitate the healing process following percutaneous catheterization procedures. Founded in 2002, the company develops and markets several key products, including the VASCADE VCS, an extravascular and bioabsorbable femoral access closure system that promotes rapid hemostasis while reducing complications for patients. Additionally, Cardiva offers the Cardiva CATALYST, a manual compression assistance device that enhances coagulation and provides temporary hemostasis. The company also manufactures the VASCADE MVP, designed for multi-site venous closure in electrophysiology procedures. Cardiva Medical primarily serves physicians and cardiac centers across the United States, focusing on transforming vascular closure to benefit patients and healthcare providers.

MiMedx Group, Inc. is a biopharmaceutical company based in Marietta, Georgia, focused on developing and marketing regenerative biologics derived from human placental tissue allografts. Utilizing its proprietary PURION Process, the company employs aseptic processing techniques and terminal sterilization to create a range of allografts. Key products include EpiFix, a membrane designed for chronic wound treatment, and AmnioFix, which is used in surgical procedures. Other offerings consist of AmnioCord and EpiCord, dehydrated human umbilical cord allografts, and AmnioFill, a connective tissue matrix. MiMedx's products cater to various healthcare sectors, including wound care, burns, surgical applications, orthopedics, sports medicine, ophthalmics, and dentistry. The company distributes its products through a direct sales force, independent agents, and third-party representatives.

Cognate BioServices, Inc. is a Memphis, Tennessee-based company specializing in the development and manufacturing of cell and cell-mediated gene therapy products for biotechnology firms and institutions across the United States. Founded in 2002, the company operates as a fully-integrated contract bioservices organization, offering a wide range of services that include process development, regulatory support, assay development, preclinical services, and cell banking. Cognate BioServices is recognized for its expertise in manufacturing cell-based products under current Good Manufacturing Practice (cGMP) conditions, and it employs advanced techniques in cryopreservation and cell isolation and expansion. The company is strategically partnered with Akron Biotechnology, which enhances its capabilities in serving the biotechnology sector.

Sonendo, Inc. is a medical technology company based in Laguna Hills, California, specializing in innovative solutions for root canal therapy. Founded in 2006, the company has developed the GentleWave System, a technology platform that enhances the cleaning and disinfection of tooth structures without compromising integrity. This system significantly improves clinical outcomes and practice efficiency compared to traditional root canal methods. In addition to its product offerings, Sonendo is the parent company of TDO Software, which provides widely used practice management software for endodontic professionals. The software integrates various functionalities, including imaging and communication tools, to streamline practice workflows. Through its focus on advanced dental technologies, Sonendo aims to address the global challenge of tooth decay, ultimately promoting better dental health.

Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, specializing in the development and commercialization of minimally invasive and non-invasive devices and treatments. Its diverse product portfolio includes platforms such as Venus Versa, a multi-treatment solution for aesthetic procedures; Venus Legacy, designed for complex face and body needs; and Venus Viva, a customizable skin resurfacing device. The company also offers solutions for hair restoration, including NeoGraft and ARTAS robotic systems, which facilitate follicle harvesting and implantation. Other products address skin tightening, fat reduction, and vaginal health restoration. Venus Concept is recognized for its innovative approach and commitment to enhancing patient experiences within the medical aesthetics sector, generating a significant portion of its revenue from the United States.

Cognate BioServices, Inc. is a Memphis, Tennessee-based company specializing in the development and manufacturing of cell and cell-mediated gene therapy products for biotechnology firms and institutions across the United States. Founded in 2002, the company operates as a fully-integrated contract bioservices organization, offering a wide range of services that include process development, regulatory support, assay development, preclinical services, and cell banking. Cognate BioServices is recognized for its expertise in manufacturing cell-based products under current Good Manufacturing Practice (cGMP) conditions, and it employs advanced techniques in cryopreservation and cell isolation and expansion. The company is strategically partnered with Akron Biotechnology, which enhances its capabilities in serving the biotechnology sector.

BioTissue is a medical technology company headquartered in Miami, Florida, that specializes in regenerative medicine using human amniotic and umbilical cord tissues. Established in 2001, the company has developed a platform that processes these tissues while preserving their natural biological and structural integrity. BioTissue's innovative products are designed to meet unmet clinical needs in various fields, including eye care, wound care, and orthopedics. By leveraging the anti-inflammatory, anti-scarring, and anti-angiogenesis properties of placental tissues, BioTissue enables healthcare professionals to enhance healing outcomes for patients.

Encore Dermatology is a privately held, fully-integrated dermatology company based in Malvern, Pennsylvania, established in 2015. The company specializes in delivering prescription therapies and medical devices to dermatologists, focusing on a variety of medical dermatology products. These offerings address several topical disease states, including conditions like acne and atopic dermatitis, thereby facilitating enhanced skincare and treatment options for patients. Through its comprehensive approach, Encore Dermatology aims to improve patient outcomes and streamline the dermatological care process.

EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing ophthalmic products for the treatment of eye diseases in the United States and Europe. The company offers several FDA-approved products, including ILUVIEN for diabetic macular edema, YUTIQ for chronic non-infectious uveitis, DEXYCU for post-operative ocular inflammation, and Retisert for posterior segment uveitis. Additionally, EyePoint is advancing its pipeline with innovative therapies such as EYP-1901, targeting wet age-related macular degeneration and diabetic retinopathy, and YUTIQ50 for uveitis. The company employs its proprietary Durasert and Verisome technology platforms to create sustained-release drug delivery systems that provide controlled drug delivery over extended periods. EyePoint has established strategic collaborations with various organizations to enhance its product offerings and has a commercial alliance for the joint promotion of DEXYCU. Founded in 1987 and headquartered in Watertown, Massachusetts, EyePoint was formerly known as pSivida Corp. and rebranded in March 2018.

COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.

Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, specializing in the development and commercialization of minimally invasive and non-invasive devices and treatments. Its diverse product portfolio includes platforms such as Venus Versa, a multi-treatment solution for aesthetic procedures; Venus Legacy, designed for complex face and body needs; and Venus Viva, a customizable skin resurfacing device. The company also offers solutions for hair restoration, including NeoGraft and ARTAS robotic systems, which facilitate follicle harvesting and implantation. Other products address skin tightening, fat reduction, and vaginal health restoration. Venus Concept is recognized for its innovative approach and commitment to enhancing patient experiences within the medical aesthetics sector, generating a significant portion of its revenue from the United States.

Xenex is a company dedicated to reducing healthcare-associated infections (HAIs) through its innovative disinfection technology. Founded in 2009 and headquartered in San Antonio, Texas, Xenex develops a portable ultraviolet room disinfection system that employs pulsed xenon UV light to effectively eliminate harmful microorganisms, including bacteria and viruses, in healthcare environments. Since its commercial introduction in 2010, Xenex's devices have been integrated into infection control protocols in nearly three hundred hospitals across the United States. The company's mission focuses on saving lives and alleviating suffering by significantly lowering the bacterial load that contributes to the risk of HAIs, thereby protecting patients, healthcare staff, and the financial health of medical facilities.

Prolacta Bioscience Inc. is a life science company based in Duarte, California, specializing in the development and production of human milk-based nutritional products for premature and critically ill infants in neonatal intensive care units (NICUs). Established in 1999, Prolacta is recognized for its innovative approach, being the first and only company to offer a human milk fortifier made entirely from human milk. The company's product line includes human milk fortifiers, caloric fortifiers, standardized human milk, and ready-to-feed formulas specifically designed to meet the unique nutritional needs of vulnerable infants. Prolacta operates a pharmaceutical-grade processing facility that employs patented methods to ensure the safety and quality of its products. By focusing on advancing the science of human milk, Prolacta aims to significantly improve the health outcomes of critically ill infants through its specialized formulations and commitment to research.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

Suneva Medical, Inc. is a medical technology company based in San Diego, California, specializing in the development, manufacturing, and commercialization of innovative aesthetic products for the dermatology, plastic, and cosmetic surgery markets. The company’s flagship product, Bellafill, is a unique dermal filler that boasts five-year safety and efficacy data and is approved for correcting facial acne scars in addition to treating nasolabial folds. Suneva Medical also offers Puregraft, a fat grafting solution that enhances long-term graft retention, as well as a platelet-rich plasma platform for optimal platelet concentrate processing and Silhouette InstaLift resorbable sutures for cosmetic facial procedures. Founded in 2008, Suneva Medical aims to provide differentiated products that enhance patient satisfaction and create significant opportunities for healthcare practitioners.

TearScience, Inc. is a medical device company based in Morrisville, North Carolina, specializing in the identification, diagnosis, and treatment of meibomian gland disease (MGD), a primary cause of dry eye affecting millions worldwide. Founded in 2005, TearScience has developed innovative devices to address evaporative dry eye, including the LipiFlow Activator, which delivers automated therapeutic energies to treat the meibomian glands, and the LipiScan, an imaging tool that allows eye care professionals to assess gland health. The company's integrated system enables effective management of MGD, which is often underestimated despite being a leading contributor to dry eye symptoms such as irritation, dryness, and visual disturbances. As a subsidiary of Johnson & Johnson Surgical Vision, TearScience continues to advance its mission of improving patient outcomes through early detection and treatment of this chronic condition.

Kona Medical, Inc. is a medical technology company that specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Established in 2009 by Dr. Michael Gertner, the company focuses on addressing the challenges posed by drug-resistant hypertension through innovative approaches, particularly renal artery denervation. Its flagship product, Surround Sound, employs ultrasound imaging to precisely guide the delivery of focused ultrasound energy for renal denervation, offering a less invasive alternative to traditional treatments. Based in Issaquah, Washington, Kona Medical integrates Dr. Gertner's inventions with assets from Therus Corporation, enhancing its capabilities in therapeutic focused ultrasound.

AxoGen, Inc. is a company focused on developing and commercializing innovative solutions for the repair and regeneration of peripheral nerve injuries. Based in Alachua, Florida, and founded in 2002, AxoGen offers a range of products designed for effective surgical procedures, including the AVANCE Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. Additionally, it provides the Axotouch Two-Point Discriminator, a device used to assess the innervation density of skin. AxoGen's offerings are aimed at surgeons and healthcare providers, ensuring clinically and economically effective solutions for nerve repair. The company also has a strategic partnership with the American Tissue Services Foundation for tissue recovery and distributes its products across the United States and several international markets, including Canada, Germany, the United Kingdom, Spain, and South Korea.

QSpex Technologies, Inc. is an optical service center based in Alpharetta, Georgia, that specializes in producing high-quality finished eyewear in the United States. Founded in 2007, the company developed a patented method for manufacturing premium lenses directly in optical offices, allowing for a cost-effective and efficient process. Utilizing advanced touchless transfer technology, QSpex enables the quick fabrication of lenses, including single vision, progressive, anti-reflective, photochromic, and polar options, with lens treatments integrated during the production process. This innovative approach allows eyewear providers to deliver finished products to patients on the same day as their eye exams. However, the company filed for voluntary liquidation under Chapter 7 in June 2020.

PreCision Dermatology is a rapidly growing company dedicated to advancing skincare through innovative therapies. It focuses on developing products that enhance the delivery of active ingredients to the skin, reducing side effects and strengthening the skin's natural barrier. The company's portfolio addresses various dermatological conditions like atopic dermatitis, acne, and rosacea. PreCision Dermatology expands its offerings through internal research, acquisitions, licensing agreements, and strategic partnerships.

Revance Therapeutics, Inc. is a biotechnology company that specializes in the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic indications. The company's lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various stages of clinical trials for treatments including glabellar lines, cervical dystonia, adult upper limb spasticity, plantar fasciitis, and chronic migraine. Revance is also advancing DAXI for aesthetic applications such as forehead lines and lateral canthal lines. Additionally, the company is developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic uses, alongside a biosimilar formulation akin to BOTOX. Revance has established collaboration agreements for the development and commercialization of its biosimilar products. Founded in 1999 and headquartered in Newark, California, Revance was previously known as Essentia Biosystems, Inc., having rebranded in 2005. The company is committed to enhancing its portfolio in dermatology and aesthetic medicine, including a range of dermal fillers and a platform for aesthetic services.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

Yantai Beacon Medical Technology Co., Ltd., founded in 2012 and headquartered in Yantai, China, specializes in the manufacture of medical equipment, notably medical gas systems and oxygen supply systems. The company also offers purification engineering services. Originally established in 1999 as Yantai Beacon Group Company Limited, it operates as a subsidiary of Bright Future (Hong Kong) Holding Ltd. Through its innovative solutions, Yantai Beacon Medical aims to enhance healthcare delivery by providing essential medical technologies.

Kona Medical, Inc. is a medical technology company that specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Established in 2009 by Dr. Michael Gertner, the company focuses on addressing the challenges posed by drug-resistant hypertension through innovative approaches, particularly renal artery denervation. Its flagship product, Surround Sound, employs ultrasound imaging to precisely guide the delivery of focused ultrasound energy for renal denervation, offering a less invasive alternative to traditional treatments. Based in Issaquah, Washington, Kona Medical integrates Dr. Gertner's inventions with assets from Therus Corporation, enhancing its capabilities in therapeutic focused ultrasound.

BreatheAmerica is a healthcare company that operates outpatient clinics dedicated to treating patients with chronic airway diseases, including allergies, sinusitis, and asthma. Founded in 2006 by Joseph C. Hutts and Derril Reeves in Nashville, Tennessee, the company focuses on improving healthcare delivery for individuals suffering from these conditions. BreatheAmerica's treatment facilities emphasize understanding the root causes of symptoms and developing personalized treatment plans, which enable patients to start their care promptly and enhance the likelihood of successful outcomes. By prioritizing exceptional patient experiences, BreatheAmerica aims to improve health outcomes while also reducing overall healthcare expenditures.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

QSpex Technologies, Inc. is an optical service center based in Alpharetta, Georgia, that specializes in producing high-quality finished eyewear in the United States. Founded in 2007, the company developed a patented method for manufacturing premium lenses directly in optical offices, allowing for a cost-effective and efficient process. Utilizing advanced touchless transfer technology, QSpex enables the quick fabrication of lenses, including single vision, progressive, anti-reflective, photochromic, and polar options, with lens treatments integrated during the production process. This innovative approach allows eyewear providers to deliver finished products to patients on the same day as their eye exams. However, the company filed for voluntary liquidation under Chapter 7 in June 2020.

Kona Medical, Inc. is a medical technology company that specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Established in 2009 by Dr. Michael Gertner, the company focuses on addressing the challenges posed by drug-resistant hypertension through innovative approaches, particularly renal artery denervation. Its flagship product, Surround Sound, employs ultrasound imaging to precisely guide the delivery of focused ultrasound energy for renal denervation, offering a less invasive alternative to traditional treatments. Based in Issaquah, Washington, Kona Medical integrates Dr. Gertner's inventions with assets from Therus Corporation, enhancing its capabilities in therapeutic focused ultrasound.

NeoVista Inc is focused on developing medical technologies aimed at improving the treatment of wet age-related macular degeneration (AMD), a condition that affects over 5 million people globally and is a leading cause of blindness among individuals over the age of 50. The company is engaged in clinical studies to validate its innovative technology, which shows promise in enhancing patient care and alleviating the challenges posed by this debilitating condition for both patients and healthcare providers. Through its efforts, NeoVista aims to significantly impact the quality of life for those affected by wet AMD.

Abiomed is a company that specializes in mechanical circulatory support devices aimed at assisting heart failure patients. It develops, manufactures, and markets products designed to improve blood flow and temporarily aid the heart's pumping function, allowing the organ to rest, heal, and recover. Its devices are primarily utilized in cardiac catheterization labs by interventional cardiologists and in surgical settings by heart surgeons. These products are essential for patients requiring hemodynamic support before, during, or after procedures such as angioplasty and heart surgery. A significant portion of Abiomed's revenue is generated from its Impella product portfolio, which includes advanced percutaneous micro heart pumps equipped with integration motors and sensors.

IntegenX Inc. is a developer of innovative human DNA identification solutions headquartered in Pleasanton, California. Founded in 2003, the company specializes in rapid DNA technology for forensics and law enforcement applications. IntegenX's technology platforms integrate advanced fluidics, optics, biochemistry, and software to create automated sample-to-answer products for human identity testing. The company offers a range of products, including the RapidHIT System, which delivers standardized DNA profiles from various human samples, and the RapidHIT GlobalFiler Express Kit for processing crime scene samples directly within the cartridge. Additionally, IntegenX provides other tools like the Apollo series for DNA sequencing and sample preparation. The company distributes its products in multiple international markets, enhancing capabilities in human identification for law enforcement agencies worldwide.

Grupo Biotoscana is a biopharmaceutical company based in Latin America, formed through the merger of two established specialty pharmaceutical firms with over 25 years of experience each. The company focuses on developing, manufacturing, and selling pharmaceutical products aimed at addressing unmet medical needs, particularly in oncology, hematology, severe infectious diseases, and rare genetic disorders. Grupo Biotoscana is recognized for its expertise in complex therapeutic areas and maintains long-term collaborations with prominent global pharmaceutical companies, enhancing its ability to deliver specialized treatments and innovative solutions in the healthcare sector.

BreatheAmerica is a healthcare company that operates outpatient clinics dedicated to treating patients with chronic airway diseases, including allergies, sinusitis, and asthma. Founded in 2006 by Joseph C. Hutts and Derril Reeves in Nashville, Tennessee, the company focuses on improving healthcare delivery for individuals suffering from these conditions. BreatheAmerica's treatment facilities emphasize understanding the root causes of symptoms and developing personalized treatment plans, which enable patients to start their care promptly and enhance the likelihood of successful outcomes. By prioritizing exceptional patient experiences, BreatheAmerica aims to improve health outcomes while also reducing overall healthcare expenditures.

Entellus Medical, doing business as Stryker ENT, is a medical device company based in Plymouth, Minnesota, specializing in innovative solutions for ear, nose, and throat (ENT) treatments. Founded in 2006, Entellus develops and commercializes minimally invasive products aimed at addressing chronic sinusitis, eustachian tube dysfunction, and nasal airway obstruction. Its product lineup includes the XprESS ENT dilation system, which offers versatility for sinus and eustachian tube procedures, and the FinESS Sinus Treatment, a direct and effective method for treating chronic rhinosinusitis that minimizes invasiveness and recovery time. The company also provides a range of surgical instruments, imaging solutions, and other tools that enhance patient care while reducing discomfort and the need for general anesthesia. By collaborating with researchers and clinicians, Entellus Medical works to meet the unmet needs of physicians and patients alike, thereby improving treatment outcomes in the ENT field.

Revance Therapeutics, Inc. is a biotechnology company that specializes in the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic indications. The company's lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various stages of clinical trials for treatments including glabellar lines, cervical dystonia, adult upper limb spasticity, plantar fasciitis, and chronic migraine. Revance is also advancing DAXI for aesthetic applications such as forehead lines and lateral canthal lines. Additionally, the company is developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic uses, alongside a biosimilar formulation akin to BOTOX. Revance has established collaboration agreements for the development and commercialization of its biosimilar products. Founded in 1999 and headquartered in Newark, California, Revance was previously known as Essentia Biosystems, Inc., having rebranded in 2005. The company is committed to enhancing its portfolio in dermatology and aesthetic medicine, including a range of dermal fillers and a platform for aesthetic services.

NeoVista Inc is focused on developing medical technologies aimed at improving the treatment of wet age-related macular degeneration (AMD), a condition that affects over 5 million people globally and is a leading cause of blindness among individuals over the age of 50. The company is engaged in clinical studies to validate its innovative technology, which shows promise in enhancing patient care and alleviating the challenges posed by this debilitating condition for both patients and healthcare providers. Through its efforts, NeoVista aims to significantly impact the quality of life for those affected by wet AMD.

Symphogen specializes in the development of recombinant polyclonal antibodies (rpAbs), a novel biopharmaceutical class. The company focuses on creating treatments and prophylactics for severe human diseases, with a particular emphasis on cancer and infectious diseases. Their pipeline includes rpAb compositions for treating idiopathic thrombocytopenic purpura, preventing hemolytic disease in newborns, and mitigating adverse reactions from smallpox vaccinations, aiming to facilitate faster cancer treatment initiation and enhance overall treatment success.

Endologix, Inc. is a medical device company that specializes in developing, manufacturing, marketing, and selling innovative solutions for the treatment of abdominal aortic aneurysms (AAA) both in the United States and internationally. The company offers a range of minimally invasive endovascular aneurysm repair (EVAR) products, including the AFX Endovascular AAA System, VELA Proximal Endograft, and Ovation abdominal stent graft system. Additionally, Endologix provides an endovascular aneurysm sealing (EVAS) system designed to seal aneurysms while maintaining blood flow to the legs. Their product offerings also include various extensions and accessories to tailor treatments to individual patient anatomies. Founded in 1992 and headquartered in Irvine, California, Endologix has a direct sales force as well as a network of third-party distributors and agents to market its products. The company was previously known as Radiance Medical Systems, Inc. until its name change in May 2002.

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

Accumetrics is a privately-held company based in San Diego, California, that specializes in the development, manufacturing, and marketing of the VerifyNow System, a suite of assays designed to assess platelet function. Founded in 1996, Accumetrics initially sold to Radiometer in 2000, but was repurchased by its management and investors in 2003. The VerifyNow System allows for the measurement of individual responses to various antiplatelet agents, providing critical diagnostic instrumentation and test kits that support clinicians in personalizing antiplatelet therapy for improved patient outcomes.

MedAvante, Inc. is a company that specializes in technology-enabled signal detection solutions for clinical trials focused on central nervous system disorders. Founded in 2002 and based in Hamilton, New Jersey, MedAvante offers a range of services including the Virgil Investigative Study Platform for site-based assessments and MedAvante Central Ratings for live assessments conducted by remote clinicians. The company also provides scientific risk reduction services such as rater qualification and training, central review, and remote ratings, which help maintain the integrity of trial data by minimizing bias and variability. MedAvante has established a standardized group of expert Central raters who conduct live interviews with trial subjects via videoconferencing or telephone, contributing to successful outcomes in numerous global trials. Since May 2017, MedAvante operates as a subsidiary of WIRB - Copernicus Group, Inc.

Healthcare Brands International (HBI) is a new company helping to turn innovative medical product technology into successful consumer brands.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.

Complete Genomics is a developer of advanced DNA sequencing technology focused on human genome sequencing and analysis. The company offers a comprehensive genomics analysis platform that integrates its proprietary sequencing technology with informatics and data management software. This combination allows Complete Genomics to deliver high-quality, affordable DNA sequencing services that facilitate large-scale research into the genetic mechanisms underlying drug responses and complex diseases. By providing ready-to-use genomic data, Complete Genomics aims to enhance the capabilities of researchers in the field of genomics and contribute to advancements in personalized medicine.

TearScience, Inc. is a medical device company based in Morrisville, North Carolina, specializing in the identification, diagnosis, and treatment of meibomian gland disease (MGD), a primary cause of dry eye affecting millions worldwide. Founded in 2005, TearScience has developed innovative devices to address evaporative dry eye, including the LipiFlow Activator, which delivers automated therapeutic energies to treat the meibomian glands, and the LipiScan, an imaging tool that allows eye care professionals to assess gland health. The company's integrated system enables effective management of MGD, which is often underestimated despite being a leading contributor to dry eye symptoms such as irritation, dryness, and visual disturbances. As a subsidiary of Johnson & Johnson Surgical Vision, TearScience continues to advance its mission of improving patient outcomes through early detection and treatment of this chronic condition.

White Pine Medical, Inc. is a private equity firm specializing in late stage investing. The firm seeks to invest in medical device companies. The company was founded in 2010 and is based in Park City, Utah.

ikaSystems Corporation is a provider of cloud-based enterprise resource planning technology tailored for the healthcare sector, particularly serving health insurers in their commercial, Medicare, and Medicaid operations. Founded in 1999 and headquartered in Southborough, Massachusetts, the company offers a comprehensive suite of solutions designed to streamline business processes and enhance operational efficiency. Key offerings include member, provider, and employer portals that facilitate administrative self-service and automate various processes such as claims submission and eligibility verification. Additionally, ikaSystems provides robust tools for claims administration, premium billing, and data warehousing, as well as applications aimed at improving care management and quality assurance. Their technology supports healthcare payers in navigating complex sales, marketing, and regulatory requirements, ultimately enabling clients to improve their business efficiency across various sectors, including telecommunications and financial services.

Velcera is a specialty pharmaceutical company with a passion for assuring pets receive the medicines they need to support excellent overall health. At Velcera, they are dedicated to developing innovative, high-quality products for the pet health market. They comply with the highest standards of practice through all phases, from development to manufacturing to marketing.

Revance Therapeutics, Inc. is a biotechnology company that specializes in the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic indications. The company's lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various stages of clinical trials for treatments including glabellar lines, cervical dystonia, adult upper limb spasticity, plantar fasciitis, and chronic migraine. Revance is also advancing DAXI for aesthetic applications such as forehead lines and lateral canthal lines. Additionally, the company is developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic uses, alongside a biosimilar formulation akin to BOTOX. Revance has established collaboration agreements for the development and commercialization of its biosimilar products. Founded in 1999 and headquartered in Newark, California, Revance was previously known as Essentia Biosystems, Inc., having rebranded in 2005. The company is committed to enhancing its portfolio in dermatology and aesthetic medicine, including a range of dermal fillers and a platform for aesthetic services.

Molecular Partners is a clinical-stage biopharmaceutical company dedicated to advancing modern medicine through the development of innovative therapies. The company specializes in a novel class of small protein therapeutics known as DARPin therapeutics, which are designed to target serious diseases, including cancer and sight-threatening disorders. Molecular Partners' product pipeline is organized into three primary areas: ophthalmology, focusing on therapies for retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, which includes DARPin candidates that feature unique mechanisms of action; and additional therapeutic areas. The firm's commitment to developing potent and versatile treatments positions it at the forefront of biopharmaceutical innovation.

Entellus Medical, doing business as Stryker ENT, is a medical device company based in Plymouth, Minnesota, specializing in innovative solutions for ear, nose, and throat (ENT) treatments. Founded in 2006, Entellus develops and commercializes minimally invasive products aimed at addressing chronic sinusitis, eustachian tube dysfunction, and nasal airway obstruction. Its product lineup includes the XprESS ENT dilation system, which offers versatility for sinus and eustachian tube procedures, and the FinESS Sinus Treatment, a direct and effective method for treating chronic rhinosinusitis that minimizes invasiveness and recovery time. The company also provides a range of surgical instruments, imaging solutions, and other tools that enhance patient care while reducing discomfort and the need for general anesthesia. By collaborating with researchers and clinicians, Entellus Medical works to meet the unmet needs of physicians and patients alike, thereby improving treatment outcomes in the ENT field.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

QSpex Technologies, Inc. is an optical service center based in Alpharetta, Georgia, that specializes in producing high-quality finished eyewear in the United States. Founded in 2007, the company developed a patented method for manufacturing premium lenses directly in optical offices, allowing for a cost-effective and efficient process. Utilizing advanced touchless transfer technology, QSpex enables the quick fabrication of lenses, including single vision, progressive, anti-reflective, photochromic, and polar options, with lens treatments integrated during the production process. This innovative approach allows eyewear providers to deliver finished products to patients on the same day as their eye exams. However, the company filed for voluntary liquidation under Chapter 7 in June 2020.

Accumetrics is a privately-held company based in San Diego, California, that specializes in the development, manufacturing, and marketing of the VerifyNow System, a suite of assays designed to assess platelet function. Founded in 1996, Accumetrics initially sold to Radiometer in 2000, but was repurchased by its management and investors in 2003. The VerifyNow System allows for the measurement of individual responses to various antiplatelet agents, providing critical diagnostic instrumentation and test kits that support clinicians in personalizing antiplatelet therapy for improved patient outcomes.

Complete Genomics is a developer of advanced DNA sequencing technology focused on human genome sequencing and analysis. The company offers a comprehensive genomics analysis platform that integrates its proprietary sequencing technology with informatics and data management software. This combination allows Complete Genomics to deliver high-quality, affordable DNA sequencing services that facilitate large-scale research into the genetic mechanisms underlying drug responses and complex diseases. By providing ready-to-use genomic data, Complete Genomics aims to enhance the capabilities of researchers in the field of genomics and contribute to advancements in personalized medicine.

Oraya Therapeutics focuses on developing noninvasive, robotically controlled treatments for inflammatory and neovascular diseases of the eye. The company is currently testing its first application of the IRay system, which aims to provide innovative solutions for eye-related conditions. By leveraging advanced technology, Oraya Therapeutics seeks to improve patient outcomes and enhance the management of ocular diseases.

Chroma Therapeutics Ltd., established in 2000, is a privately-held biotechnology company based in Abingdon, UK. It specializes in developing novel small molecule drugs for targeted cancer and inflammation treatments, drawing from chromatin biology and innovative cell accumulation approaches. The company's pipeline includes Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor for cancer treatment; and CHR-2845, a targeted solution for hematological malignancies. Chroma has built a strong network of academic collaborators and holds the first systematic assembly of intellectual property in chromatin biology, aiming to create substantial shareholder value through its innovative product pipeline targeting high-prevalence diseases.

Victory Pharma, Inc. is a specialty pharmaceutical company focused on acquiring, marketing, and developing prescription medications specifically designed to treat pain and related conditions. The company targets healthcare professionals, including rheumatologists, orthopedists, pain specialists, and primary care physicians, providing them with effective therapeutic options for chronic pain management. In addition to marketing existing products, Victory Pharma is dedicated to developing novel treatments that not only address pain effectively but also aim to reduce the side effects commonly associated with traditional pain therapeutics.

NeoVista Inc is focused on developing medical technologies aimed at improving the treatment of wet age-related macular degeneration (AMD), a condition that affects over 5 million people globally and is a leading cause of blindness among individuals over the age of 50. The company is engaged in clinical studies to validate its innovative technology, which shows promise in enhancing patient care and alleviating the challenges posed by this debilitating condition for both patients and healthcare providers. Through its efforts, NeoVista aims to significantly impact the quality of life for those affected by wet AMD.

Symphogen specializes in the development of recombinant polyclonal antibodies (rpAbs), a novel biopharmaceutical class. The company focuses on creating treatments and prophylactics for severe human diseases, with a particular emphasis on cancer and infectious diseases. Their pipeline includes rpAb compositions for treating idiopathic thrombocytopenic purpura, preventing hemolytic disease in newborns, and mitigating adverse reactions from smallpox vaccinations, aiming to facilitate faster cancer treatment initiation and enhance overall treatment success.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

Medlogics was founded upon principles of innovative, best in class solutions to local drug delivery. Accordingly, Medlogics is determined to provide safe, effective and clinically superior implantable devices to patients and their physicians, worldwide. Medlogics is focused on developing a next-generation drug eluting stent technology using a novel stent and drug delivery approach to treating coronary artery disease.

ROX Medical, Inc. is a medical device company based in San Clemente, California, that specializes in developing interventional vascular therapy devices aimed at treating uncontrolled hypertension and chronic obstructive pulmonary disease (COPD). Founded in 2003, the company has introduced the ROX Coupler, a device designed to lower blood pressure in patients with treatment-resistant hypertension by reducing peripheral vascular resistance and enhancing vascular compliance. Additionally, this device aims to improve respiratory function in COPD patients by facilitating better oxygen delivery to tissues, thus alleviating symptoms and enhancing exercise tolerance. ROX Medical is focused on delivering innovative solutions to improve patient outcomes in both hypertension and respiratory health.

Nellix has developed an original device designed to address and expand the indication for the less invasive treatment of Abdominal Aortic Aneurysms (AAAs) and Thoratic Aortic Aneurysms (TAAs). Enabling the treatment of all aneurysms with a low profiles delivery system and innovative endograft, the Nellix device has the potential to double the market size for Endovascular Aneurysms Repair (EVAR), which exceeded $800M in 2008 with a 16% CAGR (Med Tech Insight).

Accumetrics is a privately-held company based in San Diego, California, that specializes in the development, manufacturing, and marketing of the VerifyNow System, a suite of assays designed to assess platelet function. Founded in 1996, Accumetrics initially sold to Radiometer in 2000, but was repurchased by its management and investors in 2003. The VerifyNow System allows for the measurement of individual responses to various antiplatelet agents, providing critical diagnostic instrumentation and test kits that support clinicians in personalizing antiplatelet therapy for improved patient outcomes.

Oraya Therapeutics focuses on developing noninvasive, robotically controlled treatments for inflammatory and neovascular diseases of the eye. The company is currently testing its first application of the IRay system, which aims to provide innovative solutions for eye-related conditions. By leveraging advanced technology, Oraya Therapeutics seeks to improve patient outcomes and enhance the management of ocular diseases.

ATS Medical, doing business as Medtronic ATS Medical, Inc., is a medical device manufacturer that specializes in products for cardiovascular surgery. Mechanical heart valves, aortic valve graft prostheses, and other cardiovascular accessories are available from the company. Medtronic ATS Medical markets and distributes its products to the healthcare industry worldwide. ATS Medical was acquired by Medtronic on August 12, 2010

Revance Therapeutics, Inc. is a biotechnology company that specializes in the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic indications. The company's lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various stages of clinical trials for treatments including glabellar lines, cervical dystonia, adult upper limb spasticity, plantar fasciitis, and chronic migraine. Revance is also advancing DAXI for aesthetic applications such as forehead lines and lateral canthal lines. Additionally, the company is developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic uses, alongside a biosimilar formulation akin to BOTOX. Revance has established collaboration agreements for the development and commercialization of its biosimilar products. Founded in 1999 and headquartered in Newark, California, Revance was previously known as Essentia Biosystems, Inc., having rebranded in 2005. The company is committed to enhancing its portfolio in dermatology and aesthetic medicine, including a range of dermal fillers and a platform for aesthetic services.

Corium International, Inc. is a biopharmaceutical company based in Menlo Park, California, specializing in the development, manufacture, and commercialization of specialty pharmaceutical products utilizing transdermal and transmucosal delivery systems. The company offers several products, including the Clonidine Transdermal Delivery System for hypertension and Fentanyl Transdermal Delivery System for chronic pain management. Corium's pipeline includes the Twirla contraceptive patch, MicroCor hPTH(1-34) for osteoporosis, and transdermal systems for Alzheimer's disease treatment. Additionally, the company is developing Aripiprazole and Corplex Ropinirole patches targeting psychiatric disorders and Parkinson's disease, respectively. Corium has established collaborations with several pharmaceutical companies and aims to enhance therapeutic options in central nervous system healthcare. The firm has been operational since 1995 and continues to advance its innovative drug delivery technologies.

Orthovita is a Malvern, Pennsylvania-based company specializing in the development and marketing of orthobiologic and biosurgery products. Founded in 1992, Orthovita focuses on medical implants designed for the fusion, regeneration, and fixation of human bones. Additionally, the company's biosurgery platform provides innovative solutions for controlling intra-operative bleeding, also referred to as hemostasis. Orthovita distributes its products directly to healthcare providers in the United States and internationally, utilizing both independent stocking distributors and non-stocking distributors. The company has established strategic partnerships with notable organizations, enhancing its market presence and product offerings.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

Horizon Therapeutics is a biopharmaceutical company based in Northbrook, Illinois, established in 2005. The company specializes in developing prescription drugs aimed at providing relief for mild to moderate pain and managing arthritis. Among its notable product candidates are HZT-501, a proprietary fixed-dose combination of a nonsteroidal anti-inflammatory drug (NSAID) and ibuprofen, and HZT-602, which is a combination oral medication that includes naproxen and famotidine.

Oraya Therapeutics focuses on developing noninvasive, robotically controlled treatments for inflammatory and neovascular diseases of the eye. The company is currently testing its first application of the IRay system, which aims to provide innovative solutions for eye-related conditions. By leveraging advanced technology, Oraya Therapeutics seeks to improve patient outcomes and enhance the management of ocular diseases.

Millennium Pharmacy Systems is a pharmacy services provider focused on the long-term care industry, headquartered in Chicago, Illinois. The company offers a comprehensive approach to pharmacy services by integrating just-in-time dispensing with electronic prescription ordering, medication administration, and formulary management. This innovative model enables nursing and assisted living communities to enhance patient care while simultaneously reducing costs and improving operational efficiency. Millennium prioritizes medication accuracy and delivery timeliness, ensuring compliance with regulatory requirements and supporting healthcare providers in meeting their patient care objectives.

MicroPort Scientific is a medical equipment manufacturer and distributor. The company's products include cardiovascular, orthopedic, cardiac rhythm management, electrophysiology, endovascular, neurovascular, and surgical robots.

StrataGent Life Sciences, Inc. is a specialty drug therapy company focused on developing painless and non-invasive delivery methods for therapeutic treatments that typically require injection. The company's innovative approach utilizes proprietary microjet technology to administer both large and small therapeutic molecules without the need for any device to penetrate the skin. This method aims to enhance patient comfort and adherence to treatment protocols. In recognition of its pioneering work, StrataGent received a $2 million award from the Advanced Technology Program at the National Institute of Standards and Technology in May 2004 to further advance its microjet technology.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.

Alaunos Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of solid tumors, particularly through adoptive TCR-T cell therapy. Utilizing a unique gene expression and control technology, the company aims to engineer cell therapies that specifically target neoantigens resulting from genomic mutations in cancer cells. This approach is designed to enhance the precision and efficacy of cancer treatments by modulating gene expression directly at the tumor site. Currently, Alaunos is evaluating its technology in Phase 2 clinical studies, including the use of the immune system cytokine interleukin-12 for breast cancer and advanced melanoma. The company is also actively pursuing new investigational drug applications for additional targets using its advanced therapeutic platforms.

Ception Therapeutics is a biopharmaceutical company dedicated to the discovery and development of innovative therapeutics aimed at addressing significant unmet medical needs. Founded by seasoned pharmaceutical executives, the company is engaged in the commercialization of novel drugs and therapies for challenging illnesses. Ception's portfolio includes Reslizumab, which targets eosinophilic inflammatory conditions, and a class of small molecule anti-TNF receptor agents designed for potential oral administration. In addition, the company is actively developing treatments for central nervous system disorders, pain, and cancer, featuring eight proprietary products in the United States and over 100 products available internationally. Ception's research efforts are focused on creating new compounds and exploring new indications for existing therapies, underscoring its commitment to advancing healthcare solutions.

United Orthopedic Group is a global orthopedic company specializing in the manufacture of non-invasive orthopedic rehabilitation products, including a range of orthopedic braces. The company focuses on delivering high-quality solutions designed to enhance clinical effectiveness and ensure patient satisfaction. With a commitment to outstanding service for orthopedic physicians, United Orthopedic Group operates through diverse business channels and boasts strong financial support. The company is actively pursuing a growth strategy that includes acquiring new partners to expand its operations and enhance its product offerings.

Global Cord Blood Corporation is a leading provider of umbilical cord blood storage and related services in the People's Republic of China. The company specializes in testing, processing, and storing umbilical cord blood for expectant parents, facilitating access to emerging medical treatments, including cord blood transplants. Additionally, Global Cord Blood operates cord blood banks in multiple regions, including Beijing, Guangdong, and Zhejiang, where it also manages donated cord blood units and provides matching services for patients in need of transplants. Established as China Cord Blood Corporation, the company rebranded to Global Cord Blood Corporation in March 2018 and is based in Central, Hong Kong.

Healthcare Brands International (HBI) is a new company helping to turn innovative medical product technology into successful consumer brands.

NeoVista Inc is focused on developing medical technologies aimed at improving the treatment of wet age-related macular degeneration (AMD), a condition that affects over 5 million people globally and is a leading cause of blindness among individuals over the age of 50. The company is engaged in clinical studies to validate its innovative technology, which shows promise in enhancing patient care and alleviating the challenges posed by this debilitating condition for both patients and healthcare providers. Through its efforts, NeoVista aims to significantly impact the quality of life for those affected by wet AMD.

Prism Pharmaceuticals, Inc. is an acute care pharmaceutical company founded in 2004 and based in King of Prussia, Pennsylvania. The company specializes in the development and commercialization of cardiovascular injectable products in the United States. Its notable offerings include NEXTERONE, an injectable formulation of amiodarone designed for the treatment of arrhythmias, and PM103, an intravenous version of clopidogrel bisulfate. Through its innovative products, Prism Pharmaceuticals aims to address critical needs in cardiovascular care.

Chroma Therapeutics Ltd., established in 2000, is a privately-held biotechnology company based in Abingdon, UK. It specializes in developing novel small molecule drugs for targeted cancer and inflammation treatments, drawing from chromatin biology and innovative cell accumulation approaches. The company's pipeline includes Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor for cancer treatment; and CHR-2845, a targeted solution for hematological malignancies. Chroma has built a strong network of academic collaborators and holds the first systematic assembly of intellectual property in chromatin biology, aiming to create substantial shareholder value through its innovative product pipeline targeting high-prevalence diseases.

Symphogen specializes in the development of recombinant polyclonal antibodies (rpAbs), a novel biopharmaceutical class. The company focuses on creating treatments and prophylactics for severe human diseases, with a particular emphasis on cancer and infectious diseases. Their pipeline includes rpAb compositions for treating idiopathic thrombocytopenic purpura, preventing hemolytic disease in newborns, and mitigating adverse reactions from smallpox vaccinations, aiming to facilitate faster cancer treatment initiation and enhance overall treatment success.

Touchstone Health is a New York-based company specializing in providing Medicare Advantage insurance plans. The company offers a variety of Medicare Advantage product options, including zero and low dollar co-pay plans that cover medical, pharmacy, dental, and mental health benefits. Touchstone Health focuses on serving seniors, Medicare beneficiaries, and Medicaid recipients, offering programs designed to promote healthy living, education, member care, and value-added services such as dental, hearing, and vision coverage.

Breg, Inc. is a manufacturer and marketer of sports medicine products focused on orthopedic patient care. Established in 1989 and headquartered in Carlsbad, California, with operations in the United States and Mexico, the company offers a diverse array of products, including knee braces, cold therapy devices, and various bracing solutions for the hip, shoulder, elbow, spine, foot, and ankle. Additionally, Breg provides home therapy kits and pediatric products, as well as Breg Vision, a workflow management software designed to optimize patient care. The company distributes its products through a network of distributors both domestically and internationally, aiming to enhance orthopedic treatment from conservative solutions to pre- and post-surgical support.